NCT06941415 Bumetanide vs. Furosemide in Cirrhosis
| NCT ID | NCT06941415 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Stacy Johnson |
| Condition | Cirrhosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2029-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 500 participants in total. It began in 2026-06-03 with a primary completion date of 2029-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.
Eligibility Criteria
Inclusion Criteria: * History of liver cirrhosis * Clinician placed an order for bumetanide or furosemide in electronic health record within 24 hours of presentation to the hospital Exclusion Criteria: * Allergy to bumetanide or furosemide * Contraindication to diuretic administration (e.g. active bleeding, clinical suspicion of hepatorenal syndrome, hypotension) * Incarcerated or in custody of law enforcement * Diuretic ordered for purpose other than volume overload (e.g. hyperkalemia, continuation of home medication without clinical signs of volume overload) * Inpatient admission not anticipated * Not admitted to an inpatient hospital bed following initial evaluation in the emergency department
Contact & Investigator
Stacy A Johnson, MD
PRINCIPAL INVESTIGATOR
University of Utah
Frequently Asked Questions
Who can join the NCT06941415 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06941415 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 500 participants.
Is NCT06941415 currently recruiting?
Yes, NCT06941415 is actively recruiting participants. Contact the research team at andrea.white@hsc.utah.edu for enrollment information.
Where is the NCT06941415 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT06941415 clinical trial?
NCT06941415 is sponsored by Stacy Johnson. The principal investigator is Stacy A Johnson, MD at University of Utah. The trial plans to enroll 500 participants.